Latest It Compliance News

Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.

Farm Pride Foods Ltd has reported a remarkable 384% increase in net profit for the financial year ending June 2025, despite revenues remaining virtually unchanged. The company’s financial health shows signs of strengthening, though no dividends were declared.

Sequoia Financial Group reported a robust FY25 with a 13.7% rise in EBITDA and a 44% jump in funds under advice, underpinned by strategic restructuring and technology investments.

Sequoia Financial Group reported a 13.7% rise in operating profit for FY25, driven by significant growth in funds under advice and operational efficiencies. The company declared a fully franked final dividend, signaling confidence despite ongoing regulatory investigations.

Sequoia Financial Group reported steady revenue but a sharp profit decline in FY25, driven by divestments and goodwill impairment. The company simplified its business structure and strengthened governance while maintaining dividend payouts.

Beam Communications reports a pivotal FY25 marked by the divestment of its Zoleo joint venture, unlocking significant capital and delivering improved margins despite a statutory revenue decline. The company projects positive operating cash flow and growth in FY26.

Westgold Resources Limited has announced an on-market buy-back of up to 47.18 million shares, signaling a strategic move to manage capital and potentially boost shareholder value.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

Raiz Invest Limited reported robust FY25 results with revenue up 14.5% and underlying EBITDA surging 147.5%, while completing its exit from Southeast Asia and launching the new Raiz Lite product.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.